Outcomes of rotigotine clinical trials. Effects on motor and nonmotor symptoms of parkinson's disease

Neurologic Clinics

Volumn 31, Issue 3 S, 2013, Pages

  Lyons, Kelly E ^a   Pahwa, Rajesh ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical trials; Motor symptoms; Nonmotor symptoms; Parkinson's disease; Rotigotine

Indexed keywords

LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

APPLICATION SITE REACTION; BECK DEPRESSION INVENTORY; CLINICAL TRIAL (TOPIC); DAILY LIFE ACTIVITY; DISEASE DURATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSKINESIA; FATIGUE; HALLUCINATION; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; MOOD DISORDER; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARKINSON DISEASE; PLACEBO EFFECT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESSNESS; REVIEW; SLEEP DISORDER; SOMNOLENCE; SYMPTOM ASSESSMENT; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL ANALOG SCALE; VOMITING;

CLINICAL TRIALS; MOTOR SYMPTOMS; NONMOTOR SYMPTOMS; PARKINSON'S DISEASE; ROTIGOTINE;

ADMINISTRATION, CUTANEOUS; ANIMALS; DOPAMINE AGONISTS; HUMANS; MULTICENTER STUDIES AS TOPIC; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAHYDRONAPHTHALENES; THIOPHENES; TREATMENT OUTCOME;

EID: 84881529660     PISSN: 07338619     EISSN: 15579875     Source Type: Journal    
DOI: 10.1016/j.ncl.2013.04.011     Document Type: Review

References (9)

1. Parkinson Study Group Acontrolled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003, 60(12):1721-1728.
2. Watts R.L., Jankovic J., Waters C., et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007, 68(4):272-276.
3. Elmer L.W., Surmann E., Boroojerdi B., et al. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord 2012, 18(5):488-493.
4. Giladi N., Boroojerdi B., Korczyn A.D., et al. Rotigotine transdermal patch in earlyParkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22(16):2398-2404.
5. Fox S.H., Katzenschlager R., Lim S.Y., et al. The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease. Mov Disord 2011, 26(Suppl 3):S2-S41.
6. LeWitt P.A., Lyons K.E., Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 2007, 68(16):1262-1267.
7. LeWitt P.A., Boroojerdi B., Surmann E., et al. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. JNeural Transm 2012, Available at:, Accessed May 14, 2013. http://link.springer.com/article/10.1007/s00702-012-0925-5/fulltext.html.
8. Poewe W.H., Rascol O., Quinn N., et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007, 6(6):513-520.
9. Trenkwalder C., Kies B., Rudzinska M., et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011, 26(1):90-99.